M&A

CorMedix agrees to buy almost all Heron assets, adding four marketed drugs

CorMedix will pay $145 million in cash plus 14,583,333 of its shares for Heron's ZYNRELEF, APONVIE, CINVANTI and SUSTOL. Heron could also earn as much as $55 million tied to ZYNRELEF sales, plus a 5% royalty above a sales threshold. The deal needs Heron shareholder and antitrust approval and is slated to close in early 2027.

Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call